REGENXBIO Q1 net income $6.1M; revenue up 471% to $89M on Nippon Shinyaku deal

REGENXBIO Inc.

2025-Q1 EPS reported $0.12 revenue$89,012,000

Net income $6.1M ($0.12 EPS) vs net loss $63.3M ($1.38 loss) in Q1 2024.
Revenue $89.0M (vs $15.6M) driven by $71.8M license revenue from Nippon Shinyaku partnership.
Cash $272.7M; operations funded into 2H 2026; guidance excludes milestone payments and PRV.
RGX-202 Duchenne pivotal trial >50% enrolled; BLA submission on track for mid-2026.
FDA expected to accept BLA for clemidsogene lanparvovec (RGX-121) in May; potential 2025 approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.